#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Monogenic diabetes Rhabdomyosarcoma recurrent Hypocalcaemia Extraskeletal ossification Wiskott-Aldrich syndrome Neuroendocrine carcinoma of the skin Niemann-Pick disease Angiosarcoma non-metastatic Crigler-Najjar syndrome Herpes simplex Systemic candida Asthma Andersen-Tawil syndrome Chordoma Spinal cord injury cervical More trials…

    Learn about Rare Diseases

    Advanced systemic mastocytosis – Trials in Disease Marginal zone lymphoma refractory – Life with Disease Von Willebrand’s disease – Diagnostics Leukoencephalopathy Glomerulonephritis membranous – Life with Disease Adrenogenital syndrome – Life with Disease Biotinidase deficiency Adrenocortical carcinoma – Basic Information Marfan’s syndrome – Basic Information Activated PI3 kinase delta syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Itacitinib Arachis Hypogaea Extract Fluoroestradiol F-18 Triptorelin VRDN-003 Furosemide Clopidogrel Hydrogen Sulfate Bosutinib Ly3819469 Sodium Cannabidiol Quc398 Vibegron Ginisortamab ACT-1004-1239 Ads-011 Spiramycin Atl001 Adezunap Emedastine Bepirovirsen More therapies…

    Learn about Your Condition

    Prostatitis Escherichia coli Brain neoplasm Sciatica KBG syndrome Small intestine leiomyosarcoma Metastatic neoplasm Lymphocytic lymphoma Cervical dysplasia Partial lipodystrophy Drug dependence Necrotising myositis Gingival bleeding Aplasia pure red cell Infantile spasms Benign prostatic hyperplasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Paroxysmal nocturnal haemoglobinuria

  • Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Cemdisiran
    • Pozelimab
    Greece Hungary Italy Poland Romania Spain

  • Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Cemdisiran
    • Pozelimab
    • Eculizumab
    Greece Hungary Italy Poland Romania Spain

  • Study on the Long-Term Safety and Effects of OMS906 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Oms906
    Germany

  • Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Iptacopan
    Czechia France Germany Italy Lithuania The Netherlands +1

  • Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Crovalimab
    • Eculizumab
    Belgium Czechia Estonia France Germany Greece +7

  • Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Crovalimab
    • Eculizumab
    France Germany Lithuania The Netherlands Poland Portugal +3
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!